Related Experiment Video

Updated: May 7, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.7K

gp130: a promising drug target for cancer therapy

Shili Xu1, Nouri Neamati

  • 1University of Michigan, Department of Medicinal Chemistry, College of Pharmacy , North Campus Research Complex, 2800 Plymouth Road, Building 520, Ann Arbor, MI 48109 , USA neamati@umich.edu.

Expert Opinion on Therapeutic Targets
|October 9, 2013
PubMed
Abstract

Insights

Inhibition of glycoprotein 130 (gp130) signaling pathways is a promising cancer therapy. Small-molecule inhibitors targeting gp130 offer advantages over cytokine-blocking antibodies for effective cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Glycoprotein 130 (gp130) is a key receptor subunit for numerous cytokines, mediating diverse biological processes.
  • Dysregulation of gp130 signaling is implicated in various diseases, notably cancer progression.

Purpose of the Study:

  • To review the structural basis of gp130 in signal transduction.
  • To explore the role of gp130 in cancer progression and therapeutic strategies.

Main Methods:

  • Analysis of existing databases on gp130 expression and coexpression.
  • Review of structural and signaling mechanisms of gp130.
  • Examination of gp130-targeted therapeutic strategies and antagonists.

Main Results:

  • gp130 signaling networks are crucial for the progression of multiple cancer types.
  • Coexpression patterns highlight gp130's role in cancer pathways.
  • gp130 antagonists are being developed for cancer therapy.

Conclusions:

  • Inhibiting gp130 signaling presents a promising cancer therapeutic approach.
  • Small-molecule gp130 inhibitors offer advantages over cytokine-specific antibodies.
  • Successful gp130-targeted therapy requires careful consideration of dosage, duration, and patient selection.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.5K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
14.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K